Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation

Acta Oncol. 2017 Oct;56(10):1331-1333. doi: 10.1080/0284186X.2017.1324215. Epub 2017 May 10.

Affiliations

¹ a Haematology Unit and Pathology Department , S. Eugenio Hospital , Rome , Italy.
² b Neuro-Oncohematology Unit , Santa Lucia Foundation , Rome , Italy.

PMID: 28488914
DOI: 10.1080/0284186X.2017.1324215

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antimetabolites, Antineoplastic / therapeutic use*
Decitabine / therapeutic use*
Female
Humans
Janus Kinase 2 / genetics
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / pathology
Neoplasms, Multiple Primary / drug therapy*
Neoplasms, Multiple Primary / genetics
Neoplasms, Multiple Primary / pathology
Thrombocythemia, Essential / genetics
Thrombocythemia, Essential / pathology*
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Decitabine
JAK2 protein, human
Janus Kinase 2